{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:41:21Z","timestamp":1787845281668,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The aim of this study was to compare the efficacy of the combination of clomiphene citrate (CC) and letrozole to that of CC alone in inducing ovulation in infertile women with ovulatory dysfunction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A randomized controlled trial was conducted at a single academic medical center between November 2020 and December 2021. Anovulatory infertility females, aged 18 to 40, were evenly distributed by a computer-generated block of four into two treatment groups. A \u201ccombination group\u201d received a daily dose of CC (50\u00a0mg) and letrozole (2.5\u00a0mg), while a \u201cCC-alone group\u201d received a daily dose of CC alone (50\u00a0mg). The study medications were administered on days 3 through 7 of menstrual cycle. The primary outcome was the ovulation rate, defined by serum progesterone levels exceeding 3 ng\/mL at the mid-luteal phase. The secondary outcomes were ovulation induction cycle characteristics, endometrial thickness, conception rate, and adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred women (50 per group) were enrolled in the study. The mean age was not significantly different in both groups: 31.8 years in the combination group and 32.4 years in the CC-alone groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.54). The prevalence of polycystic ovary syndrome in the combination and CC-alone groups was 48% and 44%, respectively (<jats:italic>P<\/jats:italic>\u2009=\u20090.841). According to intention-to-treat analysis, the ovulation rates were 78% and 70% in the combination and CC-alone groups, respectively (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). There was no significant difference in the mean endometrial thickness or the number of dominant follicles of the groups. No serious adverse events were observed in either group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study found no significant difference between the combination of CC and letrozole and CC alone in inducing ovulation in infertile women with ovulatory dysfunction in one cycle. The small number of live births precluded any meaningful statistical analysis. Further studies are needed to validate and extend our findings beyond the scope of the current study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The study was registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.thaiclinicaltrials.org\">https:\/\/www.thaiclinicaltrials.org<\/jats:ext-link> with the following number: TCTR20201108004 and was approved on 08\/11\/2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-023-02773-7","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T14:02:36Z","timestamp":1699970556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clomiphene citrate plus letrozole versus clomiphene citrate alone for ovulation induction in infertile women with ovulatory dysfunction: a randomized controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Pattraporn","family":"Chera-aree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirikul","family":"Tanpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isarin","family":"Thanaboonyawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pitak","family":"Laokirkkiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"issue":"1","key":"2773_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.fertnstert.2012.09.023","volume":"99","author":"Practice Committee of American Society for Reproductive M","year":"2013","unstructured":"Practice Committee of American Society for Reproductive M. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril. 2013;99(1):63.","journal-title":"Fertil Steril"},{"key":"2773_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.clinbiochem.2018.03.012","volume":"62","author":"M Vander Borght","year":"2018","unstructured":"Vander Borght M, Wyns C. Fertility and infertility: definition and epidemiology. Clin Biochem. 2018;62:2\u201310.","journal-title":"Clin Biochem"},{"issue":"2","key":"2773_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/humrep\/13.2.471","volume":"13","author":"P Tuntiseranee","year":"1998","unstructured":"Tuntiseranee P, Olsen J, Chongsuvivatwong V, Limbutara S. Fecundity in Thai and European regions: results based on waiting time to pregnancy. Hum Reprod. 1998;13(2):471\u20137.","journal-title":"Hum Reprod"},{"issue":"6","key":"2773_CR4","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.beem.2011.08.001","volume":"25","author":"D Unuane","year":"2011","unstructured":"Unuane D, Tournaye H, Velkeniers B, Poppe K. Endocrine Disorders & female infertility. Best Pract Res Clin Endocrinol Metab. 2011;25(6):861\u201373.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2773_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1590\/0004-2730000003021","volume":"58","author":"RV Weiss","year":"2014","unstructured":"Weiss RV, Clapauch R. Female infertility of endocrine origin. Arq Bras Endocrinol Metabol. 2014;58(2):144\u201352.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"2","key":"2773_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2337\/diaspect.28.2.116","volume":"28","author":"CC Dennett","year":"2015","unstructured":"Dennett CC, Simon J. The role of polycystic ovary syndrome in reproductive and metabolic health: overview and approaches for treatment. Diabetes Spectr. 2015;28(2):116\u201320.","journal-title":"Diabetes Spectr"},{"issue":"3","key":"2773_CR7","first-page":"120","volume":"10","author":"I Katsikis","year":"2006","unstructured":"Katsikis I, Kita M, Karkanaki A, Prapas N, Panidis D. Anovulation and ovulation induction. Hippokratia. 2006;10(3):120\u20137.","journal-title":"Hippokratia"},{"issue":"618","key":"2773_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3399\/bjgp14X676609","volume":"64","author":"N O\u2019Flynn","year":"2014","unstructured":"O\u2019Flynn N. Assessment and treatment for people with fertility problems: NICE guideline. Br J Gen Pract. 2014;64(618):50\u20131.","journal-title":"Br J Gen Pract"},{"issue":"3","key":"2773_CR9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","volume":"110","author":"HJ Teede","year":"2018","unstructured":"Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364\u201379.","journal-title":"Fertil Steril"},{"issue":"3","key":"2773_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.fertnstert.2018.11.030","volume":"111","author":"RB Mejia","year":"2019","unstructured":"Mejia RB, Summers KM, Kresowik JD, Van Voorhis BJ. A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2019;111(3):571\u20138e1.","journal-title":"Fertil Steril"},{"key":"2773_CR11","first-page":"1427","volume":"7","author":"M Hajishafiha","year":"2013","unstructured":"Hajishafiha M, Dehghan M, Kiarang N, Sadegh-Asadi N, Shayegh SN, Ghasemi-Rad M. Combined letrozole and clomiphene versus letrozole and clomiphene alone in infertile patients with polycystic ovary syndrome. Drug Des Devel Ther. 2013;7:1427\u201331.","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"2773_CR12","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/oxfordjournals.humrep.a137165","volume":"5","author":"Y Gonen","year":"1990","unstructured":"Gonen Y, Casper RF. Sonographic determination of a possible adverse effect of clomiphene citrate on endometrial growth. Hum Reprod. 1990;5(6):670\u20134.","journal-title":"Hum Reprod"},{"key":"2773_CR13","doi-asserted-by":"crossref","unstructured":"John M, Randall AT. Cervical mucus score and in vitro sperm mucus interaction in spontaneous and clomiphene citrate cycles. Fertil Steril. 1991;Volume\u00a056, Issue 3:Pages 465-8.","DOI":"10.1016\/S0015-0282(16)54541-5"},{"issue":"6","key":"2773_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/humupd\/dmw025","volume":"22","author":"AH Balen","year":"2016","unstructured":"Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687\u2013708.","journal-title":"Hum Reprod Update"},{"issue":"Suppl 1","key":"2773_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10549-007-9696-3","volume":"105","author":"AS Bhatnagar","year":"2007","unstructured":"Bhatnagar AS. The discovery and mechanism of action of letrozole. Breast Cancer Res Treat. 2007;105(Suppl 1):7\u201317.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2773_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1056\/NEJMoa1313517","volume":"371","author":"RS Legro","year":"2014","unstructured":"Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus Clomiphene for Infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119\u201329.","journal-title":"N Engl J Med"},{"issue":"5 Suppl 1","key":"2773_CR17","first-page":"187","volume":"86","author":"Practice Committee of the American Society for Reproductive M","year":"2006","unstructured":"Practice Committee of the American Society for Reproductive M. Use of clomiphene citrate in women. Fertil Steril. 2006;86(5 Suppl 1):187\u201393.","journal-title":"Fertil Steril"},{"issue":"1","key":"2773_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijgo.2010.11.011","volume":"113","author":"MG Munro","year":"2011","unstructured":"Munro MG, Critchley HO, Broder MS, Fraser IS, Disorders FWGoM. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3\u201313.","journal-title":"Int J Gynaecol Obstet"},{"issue":"2 Pt 1","key":"2773_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/AOG.0b013e3181ca4b3a","volume":"115","author":"GE Hale","year":"2010","unstructured":"Hale GE, Manconi F, Luscombe G, Fraser IS. Quantitative measurements of menstrual blood loss in ovulatory and anovulatory cycles in middle- and late-reproductive age and the menopausal transition. Obstet Gynecol. 2010;115(2 Pt 1):249\u201356.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2773_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","volume":"81","author":"EA-SPCWG Rotterdam","year":"2004","unstructured":"Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19\u201325.","journal-title":"Fertil Steril"},{"issue":"1","key":"2773_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5455\/medarh.2016.70.39-43","volume":"70","author":"M Hajder","year":"2016","unstructured":"Hajder M, Hajder E, Husic A. The effects of total motile sperm count on spontaneous pregnancy rate and pregnancy after IUI treatment in couples with male factor and unexplained infertility. Med Arch. 2016;70(1):39\u201343.","journal-title":"Med Arch"},{"issue":"4","key":"2773_CR22","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.fertnstert.2014.08.002","volume":"102","author":"G Harbin Consensus Conference Worksho","year":"2014","unstructured":"Harbin Consensus Conference Workshop G. Improving the reporting of clinical trials of infertility treatments (IMPRINT): modifying the CONSORT statement. Fertil Steril. 2014;102(4):952\u20139e15.","journal-title":"Fertil Steril"},{"key":"2773_CR23","unstructured":"Female Infertility. In. In: Taylor HS, Pal L, Seli E, editors. Speroff\u2019s Clinical Gynecologic Endocrinology and Infertility. 9 ed. Wolters Kluwer; 2020."},{"issue":"3","key":"2773_CR24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/humrep\/deh677","volume":"20","author":"JR Richmond","year":"2005","unstructured":"Richmond JR, Deshpande N, Lyall H, Yates RWS, Fleming R. Follicular diameters in conception cycles with and without multiple pregnancy after stimulated ovulation induction. Hum Reprod. 2005;20(3):756\u201360.","journal-title":"Hum Reprod"},{"issue":"5","key":"2773_CR25","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00404-018-4688-6","volume":"297","author":"S Hu","year":"2018","unstructured":"Hu S, Yu Q, Wang Y, Wang M, Xia W, Zhu C. Letrozole versus clomiphene citrate in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2018;297(5):1081\u20138.","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"2773_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s42000-021-00289-z","volume":"20","author":"AP Tsiami","year":"2021","unstructured":"Tsiami AP, Goulis DG, Sotiriadis AI, Kolibianakis EM. Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis. Horm (Athens). 2021;20(3):449\u201361.","journal-title":"Horm (Athens)"},{"issue":"3","key":"2773_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/AOG.0000000000003105","volume":"133","author":"AM Eskew","year":"2019","unstructured":"Eskew AM, Bedrick BS, Hardi A, Stoll CRT, Colditz GA, Tuuli MG, et al. Letrozole compared with clomiphene citrate for unexplained infertility: a systematic review and Meta-analysis. Obstet Gynecol. 2019;133(3):437\u201344.","journal-title":"Obstet Gynecol"},{"issue":"11","key":"2773_CR28","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1080\/09513590.2017.1332174","volume":"33","author":"C Liu","year":"2017","unstructured":"Liu C, Feng G, Huang W, Wang Q, Yang S, Tan J, et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecol Endocrinol. 2017;33(11):872\u20136.","journal-title":"Gynecol Endocrinol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02773-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-023-02773-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02773-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T14:02:52Z","timestamp":1699970572000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-023-02773-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2773"],"URL":"https:\/\/doi.org\/10.1186\/s12905-023-02773-7","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"assertion":[{"value":"8 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Siriraj Institutional Review Board and all participants provided written informed consent to participate before enrollment. All methods were performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors declare that there are no personal or professional conflicts of interest and no financial support from the companies that produce and\/or distribute the drugs, devices, or materials described in this report.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"602"}}